

In The Specification:

Please amend the title of the application to read:

✓ --CTLA4-C γ 4 Fusion Proteins--

After the title please insert:

-- Cross Reference to Related Applications

This application is a continuation application of U.S.S.N. 09/227,595. Filed January 8, 1999 (pending), which is a divisional application of U.S.S.N. 08/595,590, filed on February 2, 1996 (pending). The contents of these applications are specifically incorporated herein by reference.--

Please replace pages 52 through 62 of the specification with pages 52 through 72 submitted herewith in Appendix B, which contain the Sequence Listing. New pages 52 through 72 merely add the Sequence Listing in the format required by 37 C.F.R. § 1.812(c).

Please renumber pages 63 through 73, containing the claims and the abstract as originally filed, as pages 73 through 83.

In the Claims:

✓ Please cancel Claims 1-55, 60, 64, 68, 70-91, and amend Claims 56-59, 61, 63, 65-67, and 69 as indicated below (a "version to show changes made" to amended claims is presented in Appendix A). For convenience, all pending claims, whether or not amended, are shown below:

56. (Amended) A modified CTLA4-immunoglobulin fusion protein comprising a first peptide having at least one CTLA4 activity and a second peptide comprising a C γ 4 immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to an unmodified CTLA4-immunoglobulin fusion protein.